Stiripentol in Dravet Syndrome

NCT01533506 — No longer available, Mayo Clinic

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome

Registry	NCT01533506
Status	No longer available
Study type	Expanded access
Sponsor	Mayo Clinic (Other)
Conditions	Dravet Syndrome
Interventions	stiripentol (Drug)
Dates	start 2012-02-01, primary completion 2013-02-01 (estimated), completion 2013-02-01 (estimated), first posted 2012-02-15, last updated 2013-02-28
Locations	1 site in United States

-Summary

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Expand all sections · Collapse all

+Arms and interventions

stiripentol (Drug), also known as Diacomit: Stiripentol up to 30 mg/kg/day to control seizures

+Eligibility

Sex: Female, ages: 11 Years to any

Inclusion Criteria:

* Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures

+Locations (1)

Facility	City	Country	Status
Mayo Clinic in Rochester	Rochester, Minnesota	United States

+Investigators

Elaine Wirrell, MD, Principal investigator, Mayo Clinic